Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Relacorilant i kombination med nab-paclitaxel og bevacizumab i avanceret, epitelial ovarie, primær peritoneal eller æggelør kræft

10. november 2026 opdateret af: Corcept Therapeutics

En fase 2-undersøgelse af relacorilant i kombination med nab-paclitaxel og bevacizumab i avanceret, epitelial ovarie, primær peritoneal eller æggelørkræft (Bella)

This is a Phase 2, open-label, global, multi-arm study to evaluate efficacy and safety of relacorilant in combination with other treatments in patients with gynecological cancers.

Studieoversigt

Detaljeret beskrivelse

This study is designed with the goal to add additional arms as new treatments become available. All arms will follow an independent and parallel design.

For Arms A and B, study treatment will comprise relacorilant combined with nab-paclitaxel, and bevacizumab and will begin on Cycle 1 Day 1 (C1D1). Each patient will receive relacorilant 150 mg administered orally under fed conditions, once daily for 3 consecutive days on the day before, the day of, and the day after nab-paclitaxel infusion (in Cycle 1 relacorilant is only given on 2 consecutive days, starting on C1D1), in combination with nab-paclitaxel (80 mg/m^2 intravenously [IV]) administered on Days 1, 8, and 15 of each 28-day cycle. Bevacizumab (10 mg/kg IV once every 2 weeks [Q2W]) will be administered on Days 1 and 15 of each 28-day cycle. Study treatment for Arm C will be similar to Arm A but does not include bevacizumab. Patients will receive treatment until they reach a protocol-defined event of progressive disease (PD), experience an unmanageable toxicity, or until other treatment discontinuation criteria are met.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

270

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

      • Brussels, Belgien, 1200
        • Rekruttering
        • 109
      • Charleroi, Belgien, 6000
        • Rekruttering
        • 326
      • Hasselt, Belgien, 3500
        • Rekruttering
        • 325
      • Leuven, Belgien, 3000
        • Rekruttering
        • 108
    • Belgium
      • Aalst, Belgium, Belgien, 9300
        • Rekruttering
        • 328
    • Alabama
      • Birmingham, Alabama, Forenede Stater, 35233
        • Rekruttering
        • 004
    • California
      • Palo Alto, California, Forenede Stater, 94304
        • Rekruttering
        • 150
      • San Francisco, California, Forenede Stater, 94109
        • Rekruttering
        • 278
      • San Francisco, California, Forenede Stater, 94143
        • Rekruttering
        • 014
    • Colorado
      • Aurora, Colorado, Forenede Stater, 80045
        • Rekruttering
        • 032
    • Florida
      • Fort Myers, Florida, Forenede Stater, 33901
        • Rekruttering
        • 544
      • Miami Beach, Florida, Forenede Stater, 33140
        • Rekruttering
        • 335
      • West Palm Beach, Florida, Forenede Stater, 33041
        • Rekruttering
        • 543
    • Illinois
      • Chicago, Illinois, Forenede Stater, 60637
        • Rekruttering
        • 001
    • Minnesota
      • Minneapolis, Minnesota, Forenede Stater, 55404
        • Rekruttering
        • 518
    • Missouri
      • Kansas City, Missouri, Forenede Stater, 64132
        • Rekruttering
        • 334
      • St Louis, Missouri, Forenede Stater, 63110
        • Rekruttering
        • 521
    • New Mexico
      • Albuquerque, New Mexico, Forenede Stater, 97102
        • Rekruttering
        • 292
    • Ohio
      • Centerville, Ohio, Forenede Stater, 45459
        • Rekruttering
        • 304
    • Oregon
      • Eugene, Oregon, Forenede Stater, 97401
        • Rekruttering
        • 517
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Forenede Stater, 15213
        • Rekruttering
        • 127
    • Virginia
      • Fairfax, Virginia, Forenede Stater, 22031
        • Rekruttering
        • 522
      • Norfolk, Virginia, Forenede Stater, 23502
        • Rekruttering
        • 300
    • Wisconsin
      • Milwaukee, Wisconsin, Forenede Stater, 53226
        • Rekruttering
        • 121
      • Lille, Frankrig, 59000
        • Rekruttering
        • 306
      • Nancy, Frankrig, 54100
        • Rekruttering
        • 307
      • Nice, Frankrig, 06100
        • Rekruttering
        • 310
      • Pierre-Bénite, Frankrig, 69495
        • Rekruttering
        • 324
      • Plérin, Frankrig, 22190
        • Rekruttering
        • 323
      • Toulouse, Frankrig, 31059
        • Rekruttering
        • 308
      • Catania, Italien, 95126
        • Rekruttering
        • 321
      • Milan, Italien, 20141
        • Rekruttering
        • 122
      • Milan, Italien, 20159
        • Rekruttering
        • 516
      • Pavia, Italien, 27100
        • Rekruttering
        • 295
      • Rome, Italien, 00168
        • Rekruttering
        • 124
      • Torino, Italien, 10128
        • Rekruttering
        • 293
      • Treviso, Italien, 31100
        • Rekruttering
        • 319
      • Gdynia, Polen, 81-519
        • Rekruttering
        • 341
      • Siedlce, Polen, 08-MO
        • Rekruttering
        • 329
      • Badalona, Spanien, 08916
        • Rekruttering
        • 349
      • Barcelona, Spanien, 08035
        • Rekruttering
        • 115
      • Madrid, Spanien, 28034
        • Rekruttering
        • 114
      • Valencia, Spanien, 46026
        • Rekruttering
        • 330
      • Valencia, Spanien, 46010
        • Rekruttering
        • 558
    • Gangnam-gu
      • Seoul, Gangnam-gu, Sydkorea, 06351
        • Rekruttering
        • 396
    • Goyang-si
      • Gyeonggi-do, Goyang-si, Sydkorea, 10408
        • Rekruttering
        • 397
    • Jongno-gu
      • Seoul, Jongno-gu, Sydkorea, 03080
        • Rekruttering
        • 399
    • Seocho-gu
      • Seoul, Seocho-gu, Sydkorea, 06591
        • Rekruttering
        • 523
    • Seodaemun-gu
      • Seoul, Seodaemun-gu, Sydkorea, 03722
        • Rekruttering
        • 398
    • Songpa-gu
      • Seoul, Songpa-gu, Sydkorea, 05505
        • Rekruttering
        • 403
      • Aachen, Tyskland, 52074
        • Rekruttering
        • 519
      • Berlin, Tyskland, 10117
        • Rekruttering
        • 255
      • Kempten, Tyskland, 87439
        • Rekruttering
        • 520

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Kvinde

Beskrivelse

Inclusion Criteria:

Arms A and B

  • Histologic diagnosis of epithelial ovarian, primary peritoneal, or fallopian-tube carcinoma
  • Arm A Only: Platinum-resistant disease
  • Arm B Only: Platinum-sensitive disease who had progression while receiving treatment with a poly(ADP-ribose) polymerase (PARP) inhibitor
  • Life expectancy of ≥3 months
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
  • Able to swallow and retain oral medication
  • 1 to 3 lines of prior systemic anticancer therapy
  • Adequate organ function
  • Negative pregnancy test for patients of childbearing potential

Arm C

  • Stage III or IV, recurrent, or metastatic endometrial cancer
  • Life expectancy of ≥3 months
  • ECOG performance status of 0 or 1
  • Able to swallow and retain oral medication
  • Prior treatment with a platinum agent and an approved anti-Programmed Cell Death Ligand 1 (PD[L]1) antibody
  • 1 to 2 lines of prior systemic anticancer therapy for endometrial cancer
  • Must consent to provide an available formalin-fixed paraffin-embedded (FFPE) tumor tissue block or recently cut sections
  • Adequate organ function
  • Negative pregnancy test for patients of childbearing potential

Exclusion Criteria:

Arm A and B

  • Arm A Only: Has progressed while receiving weekly paclitaxel or nab-paclitaxel
  • Prior enrollment in a clinical trial of relacorilant
  • Prior anticancer therapy related toxicities not resolved to grade ≤1
  • Any surgery within 4 weeks prior to enrollment
  • Wide-field radiation to more than 25% of marrow-bearing areas
  • Medical conditions requiring chronic or frequent treatment with corticosteroids
  • Concurrent treatment with mifepristone or other glucocorticoid receptor modulators
  • Peripheral neuropathy from any cause >Grade 1
  • Hypertension: ≥150 mm Hg systolic or ≥100 mm Hg diastolic
  • Uncontrolled condition(s) which, may confound the results of the trial or interfere with the patient's safety or participation
  • Bowel obstruction ≤12 weeks prior to study entry
  • Ascites or pleural effusions requiring therapeutic paracentesis
  • Untreated or symptomatic central nervous system metastases
  • History of other malignancy within 3 years prior to enrollment
  • Has received a live vaccine within 30 days prior to the study start date

Arm C

  • Has progressed while receiving weekly paclitaxel or nab-paclitaxel
  • Prior enrollment in a clinical trial of relacorilant
  • Prior anticancer therapy related toxicities not resolved to grade ≤1
  • Any surgery within 4 weeks prior to enrollment
  • Wide-field radiation to more than 25% of marrow-bearing areas
  • Medical conditions requiring chronic or frequent treatment with corticosteroids
  • Concurrent treatment with mifepristone or other glucocorticoid receptor modulators
  • Peripheral neuropathy from any cause >Grade 1
  • Uncontrolled condition(s) which, may confound the results of the trial or interfere with the patient's safety or participation
  • Bowel obstruction ≤12 weeks prior to study entry
  • Ascites or pleural effusions requiring therapeutic paracentesis
  • History of other malignancy within 3 years prior to enrollment
  • Has received a live vaccine within 30 days prior to the study start date
  • Patients with central nervous system metastases are not eligible, unless they have completed local therapy and have discontinued the use of corticosteroids for this indication for at least 4 weeks before starting treatment in this study.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Ikke-randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Arm A: Relacorilant in Combination with Nab-paclitaxel and Bevacizumab

In Arm A, patients with platinum-resistant ovarian cancer will receive the combination of relacorilant with nab-paclitaxel and bevacizumab.

Relacorilant is administered under fed conditions as capsules for oral dosing on the day before, the day of, and the day after nab-paclitaxel infusion.

Andre navne:
  • CORT125134

Nab-paclitaxel is administered as IV infusion on Days 1, 8, and 15 of each 28-day cycle.

Bevacizumab is administered as IV infusion on Days 1 and 15.

Eksperimentel: Arm B: Relacorilant in Combination with Nab-Paclitaxel and Bevacizumab

In Arm B, patients with platinum-sensitive ovarian cancer who have progressed while receiving treatment with a polymerase inhibitor will receive relacorilant in combination with nab-paclitaxel and bevacizumab.

Relacorilant is administered under fed conditions as capsules for oral dosing on the day before, the day of, and the day after nab-paclitaxel infusion.

Andre navne:
  • CORT125134

Nab-paclitaxel is administered as IV infusion on Days 1, 8, and 15 of each 28-day cycle.

Bevacizumab is administered as IV infusion on Days 1 and 15.

Eksperimentel: Arm C: Relacorilant in Combination with Nab-Paclitaxel

In Arm C, patients with previously-treated advanced, recurrent, or metastatic endometrial cancer will receive relacorilant in combination with nab-paclitaxel.

Relacorilant is administered under fed conditions as capsules for oral dosing on the day before, the day of, and the day after nab-paclitaxel infusion.

Andre navne:
  • CORT125134

Nab-paclitaxel is administered as IV infusion on Days 1, 8, and 15 of each 28-day cycle.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Progression-Free Survival (PFS)
Tidsramme: Date of first dose until PD or death, up to 18 months

To evaluate PFS as the time from enrollment until first documented progressive disease (PD) by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 as determined by the Investigator, or death due to any cause, whichever occurs first.

Date of first dose until PD or death, up to 18 months

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Antal patienter med en eller flere bivirkninger
Tidsramme: Dato for den første dosis op til 30 dage efter sidste dosis
Dato for den første dosis op til 30 dage efter sidste dosis
Objective Response Rate (ORR)
Tidsramme: Date of first dose until PD or death, up to 18 months

To evaluate the proportion of patients with measurable disease at Baseline who attain complete response (CR) or partial response (PR) by RECIST version 1.1.

Date of first dose until PD or death, up to 18 months
Best Overall Response Rate (BOR)
Tidsramme: Date of first dose until PD or death, up to 18 months

To evaluate the BOR by RECIST version 1.1 recorded from the date of enrollment until PD or death.

Date of first dose until PD or death, up to 18 months
Duration of Response (DOR)
Tidsramme: Time of first objective response until PD or death, up to 18 months

To evaluate DOR as the time from the first CR or PR to first objectively documented PD or death, whichever comes first.

Time of first objective response until PD or death, up to 18 months
Clinical Benefit Rate (CBR)
Tidsramme: Week 24

To evaluate CBR as the proportion of patients who attain CR, PR, or stable disease (SD) at Week 24 as per RECIST version 1.1.

Week 24
Overall Survival (OS)
Tidsramme: Date of first dose up to 6, 12, and 18 months

To evaluate the probability of OS survival at 6, 12, and 18 months.

Date of first dose up to 6, 12, and 18 months
Area under the plasma concentration-time curve (AUC) of relacorilant
Tidsramme: On Cycle 1 Day 8 (each cycle is 28 days)

To estimate exposure of relacorilant. This outcome applies to Arms B and C only.

On Cycle 1 Day 8 (each cycle is 28 days)
Maximum plasma concentration (Cmax) of relacorilant
Tidsramme: On Cycle1 Day 8 (each cycle is 28 days)

To estimate exposure of relacorilant. This outcome applies to Arms B and C only.

On Cycle1 Day 8 (each cycle is 28 days)
Trough plasma concentrations (Cmin) of relacorilant
Tidsramme: On Cycle 2 Day 8 through the last cycle (up to 12 cycles, each cycle is 28 days)

To estimate exposure of relacorilant. This outcome applies to Arms B and C only.

On Cycle 2 Day 8 through the last cycle (up to 12 cycles, each cycle is 28 days)

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Studieleder: Danny Nguyen, MD, Corcept Therapeutics

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

11. april 2025

Primær færdiggørelse (Anslået)

1. december 2027

Studieafslutning (Anslået)

1. august 2028

Datoer for studieregistrering

Først indsendt

1. april 2025

Først indsendt, der opfyldte QC-kriterier

1. april 2025

Først opslået (Faktiske)

2. april 2025

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

16. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

10. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

produkt fremstillet i og eksporteret fra U.S.A.

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner